While basal- like breast cancer is defined by its genomic signature, the majority of these cancers are negative by immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), and Her2/neu, and hence are commonly referred to as triple negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and breast cancer.